GB202020191D0 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
GB202020191D0
GB202020191D0 GBGB2020191.9A GB202020191A GB202020191D0 GB 202020191 D0 GB202020191 D0 GB 202020191D0 GB 202020191 A GB202020191 A GB 202020191A GB 202020191 D0 GB202020191 D0 GB 202020191D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2020191.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Priority to GBGB2020191.9A priority Critical patent/GB202020191D0/en
Publication of GB202020191D0 publication Critical patent/GB202020191D0/en
Priority to KR1020237023911A priority patent/KR20230121830A/ko
Priority to MX2023007140A priority patent/MX2023007140A/es
Priority to PE2023001903A priority patent/PE20240646A1/es
Priority to CA3202054A priority patent/CA3202054A1/en
Priority to CN202180093050.7A priority patent/CN116848109B/zh
Priority to PCT/GB2021/053372 priority patent/WO2022129951A1/en
Priority to IL303484A priority patent/IL303484A/en
Priority to AU2021404194A priority patent/AU2021404194A1/en
Priority to JP2023536899A priority patent/JP7730369B2/ja
Priority to CR20230256A priority patent/CR20230256A/es
Priority to EP21836606.0A priority patent/EP4263536A1/en
Priority to US17/874,564 priority patent/US11999745B2/en
Priority to JOJO/P/2023/0128A priority patent/JOP20230128A1/ar
Priority to CL2023001755A priority patent/CL2023001755A1/es
Priority to ZA2023/06305A priority patent/ZA202306305B/en
Priority to ECSENADI202344370A priority patent/ECSP23044370A/es
Priority to DO2023000125A priority patent/DOP2023000125A/es
Priority to CONC2023/0007838A priority patent/CO2023007838A2/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB2020191.9A 2019-04-23 2020-12-18 Pharmaceutical compounds Ceased GB202020191D0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GBGB2020191.9A GB202020191D0 (en) 2020-12-18 2020-12-18 Pharmaceutical compounds
EP21836606.0A EP4263536A1 (en) 2020-12-18 2021-12-20 Pharmaceutical compounds
AU2021404194A AU2021404194A1 (en) 2020-12-18 2021-12-20 Pharmaceutical compounds
CR20230256A CR20230256A (es) 2020-12-18 2021-12-20 Compuestos farmacéuticos
PE2023001903A PE20240646A1 (es) 2020-12-18 2021-12-20 Compuestos farmaceuticos
CA3202054A CA3202054A1 (en) 2020-12-18 2021-12-20 Pharmaceutical compounds
CN202180093050.7A CN116848109B (zh) 2020-12-18 2021-12-20 药物化合物
PCT/GB2021/053372 WO2022129951A1 (en) 2020-12-18 2021-12-20 Pharmaceutical compounds
IL303484A IL303484A (en) 2020-12-18 2021-12-20 Pharmaceutical compounds
KR1020237023911A KR20230121830A (ko) 2020-12-18 2021-12-20 제약 화합물
JP2023536899A JP7730369B2 (ja) 2020-12-18 2021-12-20 医薬化合物
MX2023007140A MX2023007140A (es) 2020-12-18 2021-12-20 Compuestos farmaceuticos.
US17/874,564 US11999745B2 (en) 2020-12-18 2022-07-27 Pharmaceutical compounds
JOJO/P/2023/0128A JOP20230128A1 (ar) 2020-12-18 2023-06-06 مركبات صيدلانية
CL2023001755A CL2023001755A1 (es) 2020-12-18 2023-06-15 Compuestos farmacéuticos.
ZA2023/06305A ZA202306305B (en) 2019-04-23 2023-06-15 Pharmaceutical compounds
ECSENADI202344370A ECSP23044370A (es) 2020-12-18 2023-06-15 Compuestos farmacéuticos
DO2023000125A DOP2023000125A (es) 2020-12-18 2023-06-15 Compuestos farmacéuticos
CONC2023/0007838A CO2023007838A2 (es) 2020-12-18 2023-06-15 Compuestos farmacéuticos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2020191.9A GB202020191D0 (en) 2020-12-18 2020-12-18 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
GB202020191D0 true GB202020191D0 (en) 2021-02-03

Family

ID=74221349

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2020191.9A Ceased GB202020191D0 (en) 2019-04-23 2020-12-18 Pharmaceutical compounds

Country Status (18)

Country Link
US (1) US11999745B2 (enExample)
EP (1) EP4263536A1 (enExample)
JP (1) JP7730369B2 (enExample)
KR (1) KR20230121830A (enExample)
CN (1) CN116848109B (enExample)
AU (1) AU2021404194A1 (enExample)
CA (1) CA3202054A1 (enExample)
CL (1) CL2023001755A1 (enExample)
CO (1) CO2023007838A2 (enExample)
CR (1) CR20230256A (enExample)
DO (1) DOP2023000125A (enExample)
EC (1) ECSP23044370A (enExample)
GB (1) GB202020191D0 (enExample)
IL (1) IL303484A (enExample)
JO (1) JOP20230128A1 (enExample)
MX (1) MX2023007140A (enExample)
PE (1) PE20240646A1 (enExample)
WO (1) WO2022129951A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780015B1 (en) 2011-11-18 2017-01-04 Heptares Therapeutics Limited Muscarinic m1 receptor agonists
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369184A (en) 1980-01-24 1983-01-18 Janssen Pharmaceutica N.V. 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives
JPS56110674A (en) 1980-01-24 1981-09-01 Janssen Pharmaceutica Nv Novel 11*cyclohexyl**44aryll44piperidine carboxylic acid derivative
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
JP2002515008A (ja) 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
WO1997016187A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
DE69734774D1 (de) 1996-08-26 2006-01-05 Pfizer Spirocyclische dopaminrezeptor-subtyp-liganden
JP2002505684A (ja) 1997-06-18 2002-02-19 メルク エンド カンパニー インコーポレーテッド α１ａアドレナリン受容体拮抗薬
GB9715892D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
WO1999032486A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1999032479A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists
AU2307999A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1999032489A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
CZ286152B6 (cs) 1998-03-13 2000-01-12 Miroslav Ing. Csc. Vlček Transparentní a semitransparentní difrakční prvky
KR100439357B1 (ko) 1999-05-04 2004-07-07 쉐링 코포레이션 Ｃｃｒ５ 길항제로서 유용한 피페리딘 유도체
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
BR0010593A (pt) 1999-05-04 2002-02-13 Schering Corp Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
ES2199856T3 (es) 1999-09-13 2004-03-01 Boehringer Ingelheim Pharmaceuticals, Inc. Nuevos compuestos heterociclicos, utiles como inhibidores reversibles de cisteina proteasas.
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6699880B1 (en) 1999-10-13 2004-03-02 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
US7163938B2 (en) 2000-11-28 2007-01-16 Eli Lilly And Company Substituted carboxamides
JPWO2002085890A1 (ja) 2001-04-20 2004-08-12 萬有製薬株式会社 ベンズイミダゾロン誘導体
EP1395257A1 (en) 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
GB0128378D0 (en) 2001-11-27 2002-01-16 Smithkline Beecham Plc Novel Compounds
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
ES2251624T3 (es) 2001-12-28 2006-05-01 Acadia Pharmaceuticals Inc. Analogos de la tetrahidroquinolina como los agonistas muscarinicos.
US20040171614A1 (en) 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
US7256186B2 (en) 2002-02-06 2007-08-14 Schering Corporation Gamma secretase inhibitors
PT1489078E (pt) 2002-03-28 2010-02-24 Mitsubishi Tanabe Pharma Corp Derivados de benzofurano
JPWO2003104230A1 (ja) 2002-06-07 2005-10-06 協和醗酵工業株式会社 二環性ピリミジン誘導体
HK1079787A1 (zh) 2002-07-31 2006-04-13 Ranbaxy Laboratories Limited 用作毒蕈碱受体拮抗剂的3，6-二取代的氮杂双环[3．1．0]己烷衍生物
JP4711391B2 (ja) 2002-09-30 2011-06-29 ニューロサーチ、アクティーゼルスカブ 新規１，４−ジアザビシクロアルカン誘導体及びその製造方法
RU2342388C2 (ru) 2002-11-22 2008-12-27 Джапан Тобакко Инк. Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
EP1565436B1 (en) 2002-11-27 2012-04-25 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
WO2004069828A1 (ja) 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
MXPA06000441A (es) 2003-07-17 2006-04-05 Astellas Pharma Inc Derivado de 2-acilaminotiazole o sal del mismo.
JPWO2005037269A1 (ja) 2003-10-21 2006-12-28 住友製薬株式会社 新規ピペリジン誘導体
CA2554465A1 (en) 2004-02-05 2005-08-25 Schering Corporation Piperidine derivatives useful as ccr3 antagonists
RU2006132465A (ru) 2004-02-10 2008-03-20 Ф.Хоффманн-Ля Рош Аг (Ch) Модуляторы хемокинового рецептора ccr5
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
JP2008521821A (ja) 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
JP4774995B2 (ja) 2005-01-12 2011-09-21 アステラス製薬株式会社 アシルアミノチアゾール誘導体を有効成分とする医薬組成物
EP1863490A2 (en) 2005-03-28 2007-12-12 Vertex Pharmaceuticals Incorporated Muscarinic modulators
EP1900732A4 (en) 2005-06-24 2009-11-18 Toyama Chemical Co Ltd NEW NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF
AU2006330866A1 (en) 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
ES2545907T3 (es) 2005-12-29 2015-09-16 Abbvie Inc. Inhibidores de proteína quinasa
KR20080098070A (ko) 2006-02-22 2008-11-06 버텍스 파마슈티칼스 인코포레이티드 무스카린성 수용체의 조절제로서의 스피로 축합된 피페리딘
AU2007221214A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2007284548A1 (en) 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US20130012485A1 (en) 2006-12-22 2013-01-10 Baeschlin Daniel Kaspar Organic compounds
WO2008117229A1 (en) 2007-03-23 2008-10-02 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
WO2009118370A1 (en) 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
MX2011004340A (es) 2008-10-29 2011-05-23 Gruenenthal Gmbh Espiroaminas sustituidas.
CN102256963B (zh) 2008-12-19 2014-06-11 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
EP2419419B1 (en) 2009-04-17 2014-12-03 Janssen Pharmaceutica NV 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
WO2011112825A2 (en) 2010-03-10 2011-09-15 Vanderbilt University Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same
US8822447B2 (en) 2010-04-22 2014-09-02 Janssen Pharmaceutica Nv Indazole compounds useful as ketohexokinase inhibitors
EP2563127A4 (en) 2010-04-27 2013-11-06 Merck Sharp & Dohme PROLYLCARBOXYPEPTIDASE INHIBITORS
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
JP2013528180A (ja) 2010-05-28 2013-07-08 ジーイー・ヘルスケア・リミテッド 放射性標識化合物及びその製造方法
EP2616074A1 (en) 2010-09-17 2013-07-24 Array Biopharma, Inc. Piperidinyl-substituted lactams as gpr119 modulators
EP2685828A4 (en) 2011-03-17 2014-08-13 Merck Sharp & Dohme SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS
JP2013010719A (ja) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
EP2780015B1 (en) 2011-11-18 2017-01-04 Heptares Therapeutics Limited Muscarinic m1 receptor agonists
CN107098899B (zh) 2012-09-18 2019-09-06 赫普泰雅治疗有限公司 作为毒蕈碱的m1受体激动剂的二环氮杂化合物
JP6478923B2 (ja) 2013-02-07 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート
SG11201606269WA (en) 2014-02-06 2016-09-29 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
SG11201706501VA (en) 2015-02-13 2017-09-28 Suven Life Sciences Ltd AMIDE COMPOUNDS AS 5-HT<sb>4</sb> RECEPTOR AGONISTS
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513740D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
US10501483B2 (en) 2017-10-24 2019-12-10 Allergan, Inc. Enamines and diastereo-selective reduction of enamines
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202103211D0 (en) 2021-03-08 2021-04-21 Heptares Therapeutics Ltd Pharmaceutical compounds for use in therapy

Also Published As

Publication number Publication date
JP2024504252A (ja) 2024-01-31
AU2021404194A1 (en) 2023-08-03
AU2021404194A9 (en) 2024-10-17
PE20240646A1 (es) 2024-04-04
WO2022129951A1 (en) 2022-06-23
US11999745B2 (en) 2024-06-04
JP7730369B2 (ja) 2025-08-27
MX2023007140A (es) 2023-08-25
US20220380379A1 (en) 2022-12-01
IL303484A (en) 2023-08-01
CL2023001755A1 (es) 2024-01-05
CR20230256A (es) 2023-09-29
DOP2023000125A (es) 2023-08-31
CN116848109B (zh) 2026-02-10
KR20230121830A (ko) 2023-08-21
ECSP23044370A (es) 2023-08-31
EP4263536A1 (en) 2023-10-25
CA3202054A1 (en) 2022-06-23
CO2023007838A2 (es) 2023-10-30
CN116848109A (zh) 2023-10-03
JOP20230128A1 (ar) 2023-06-06

Similar Documents

Publication Publication Date Title
GB201911928D0 (en) Pharmaceutical compounds
IL276232A (en) pharmaceutical compounds
GB202020191D0 (en) Pharmaceutical compounds
GB202010409D0 (en) Pharmaceutical compounds
GB201911944D0 (en) Pharmaceutical compounds
GB202010408D0 (en) Pharmaceutical compounds
GB201810245D0 (en) Pharmaceutical compounds
GB201810239D0 (en) Pharmaceutical compounds
GB201819961D0 (en) Pharmaceutical compounds
GB201915273D0 (en) Pharmaceutical compounds
GB201914910D0 (en) Pharmaceutical compounds
GB201819960D0 (en) Pharmaceutical compounds
GB201915932D0 (en) Pharmaceutical compounds
GB201801562D0 (en) Pharmaceutical compounds
GB202111193D0 (en) Pharmaceutical compounds
GB202200753D0 (en) Pharmaceutical compounds
GB202104097D0 (en) Pharmaceutical compounds
IL291570A (en) Pharmaceutical preparations
GB201800378D0 (en) Pharmaceutical compounds
GB202102602D0 (en) Pharmaceutical compounds
GB202201283D0 (en) Pharmaceutical compounds
GB201816369D0 (en) Pharmaceutical compounds
GB202213819D0 (en) Pharmaceutical compound
GB202117969D0 (en) Pharmaceutical compounds
GB202007163D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)